接受β受体阻滞剂联合套扎预防再出血的『非高危』急性食管胃静脉曲张破裂出血患者的生存预测
研究前瞻性纳入34个中心2011—2015年2225例肝硬化静脉曲张出血成人,最终分析581例接受非选择性β受体阻滞剂联合内镜下静脉曲张套扎预防再出血的『非高危』患者,随访1年。90例(15%)再出血、70例(12%)死亡;再出血(时间依赖协变量)升高死亡风险(校正病因特异性HR 2.57,95%CI 1.43-4.62,p=0.002);纳入基线CTP、肌酐、钠的列线图可准确分层死亡风险(一致性0.752)。
要点
- 『非高危』急性静脉曲张出血按当前推荐治疗者多数预后良好,但约五分之一死亡风险仍较高。
- 再出血作为时间依赖协变量与死亡升高相关(校正病因特异性HR 2.57,95%CI 1.43-4.62,p=0.002)。
- 基线CTP≥8和/或肌酐高或低钠血症者1年内死亡风险可观,列线图一致性0.752。
核心结论
- 多数『非高危』急性静脉曲张出血患者按当前推荐治疗预后良好,但约五分之一(CTP≥8和/或肌酐高或低钠血症)在指数出血后1年内死亡风险可观,未来临床试验应探讨择期TIPS能否降低这些患者死亡率。
研究设计与样本
- 前瞻性研究,2011—2015年在34个中心招募2225例肝硬化静脉曲张出血成人,最终纳入581例无止血失败或TIPS禁忌、接受非选择性β受体阻滞剂联合内镜下静脉曲张套扎的『非高危』患者,随访1年。
主要发现
- 随访期间90例(15%)再出血,70例(12%)死亡。
- 常规临床数据未识别出有意义的再出血预测因素。
- 再出血(作为时间依赖协变量)升高死亡风险,校正患者特征差异后病因特异性HR 2.57(95%CI 1.43-4.62,p=0.002)。
- 纳入基线CTP、肌酐和钠的列线图可准确分层死亡风险(一致性0.752)。
关键数值与推荐
- 再出血与死亡关联的校正病因特异性HR 2.57(95%CI 1.43-4.62,p=0.002)。
- 死亡风险列线图一致性0.752,纳入基线CTP、肌酐和钠。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) is the treatment of choice for high-risk acute variceal bleeding (AVB; i.e., Child-Turcotte-Pugh [CTP] B8-9+active bleeding/C10-13). Nevertheless, some 'non-high-risk' patients have poor outcomes despite the combination of non-selective beta-blockers and endoscopic variceal ligation for secondary prophylaxis. We investigated prognostic factors for re-bleeding and mortality in 'non-high-risk' AVB to identify subgroups who may benefit from more potent treatments (i.e., TIPS) to prevent further decompensation and mortality. METHODS: A total of 2,225 adults with cirrhosis and variceal bleeding were prospectively recruited at 34 centres between 2011-2015; for the purpose of this study, case definitions and information on prognostic indicators at index AVB and on day 5 were further refined in low-risk patients, of whom 581 (without failure to control bleeding or contraindications to TIPS) who were managed by non-selective beta-blockers/endoscopic variceal ligation, were finally included. Patients were followed for 1 year. RESULTS: Overall, 90 patients (15%) re-bled and 70 (12%) patients died during follow-up. Using clinical routine data, no meaningful predictors of re-bleeding were identified. However, re-bleeding (included as a time-dependent co-variable) increased mortality, even after accounting for differences in patient characteristics (adjusted cause-specific hazard ratio: 2.57; 95% CI 1.43-4.62; p = 0.002). A nomogram including CTP, creatinine, and sodium measured at baseline accurately (concordance: 0.752) stratified the risk of death. CONCLUSION: The majority of 'non-high-risk' patients with AVB have an excellent prognosis, if treated according to current recommendations. However, about one-fifth of patients, i.e. those with CTP ≥8 and/or high creatinine levels or hyponatremia, have a considerable risk of death within 1 year of the index bleed. Future clinical trials should investigate whether elective TIPS placement reduces mortality in these patients. IMPACT AND IMPLICATIONS: Pre-emptive transjugular intrahepatic portosystemic shunt placement improves outcomes in high-risk acute variceal bleeding; nevertheless, some 'non-high-risk' patients have poor outcomes despite the combination of non-selective beta-blockers and endoscopic variceal ligation. This is the first large-scale study investigating prognostic factors for re-bleeding and mortality in 'non-high-risk' acute variceal bleeding. While no clinically meaningful predictors were identified for re-bleeding, we developed a nomogram integrating baseline Child-Turcotte-Pugh score, creatinine, and sodium to stratify mortality risk. Our study paves the way for future clinical trials evaluating whether elective transjugular intrahepatic portosystemic shunt placement improves outcomes in presumably 'non-high-risk' patients who are identified as being at increased risk of death.
引用
- Balcar L, Mandorfer M, Hernández-Gea V, et al. Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding. J Hepatol. 2023. PMID: 37852414. doi:10.1016/j.jhep.2023.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。